Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + vinorelbine in HER2-positive metastatic breast cancer after progression on lapatinib-containing therapy
2009-016826-15Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and vinorelbine in HER2-enriched breast cancer (HER2+), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Progression-free survival. Started May 2010; status: completed.
02
Drugs
lapatinibvinorelbine
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2009-016826-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016826-15.